Home | News | Directories | Calendar | Maps | Contact Us | Webmail
Perelman School of Medicine at the University of Pennsylvania Advanced Search

Fiona Simpkins, M.D.

Fiona Simpkins, M.D.

faculty photo
Assistant Professor of Obstetrics and Gynecology at the Hospital of the University of Pennsylvania
Department: Obstetrics and Gynecology

Contact information
Jordan Center for Gynecologic Oncology at Penn Perelman Center for Advanced Medicine
3400 Civic Center Blvd., 3rd Floor West
Philadelphia, PA 19104
Office: 215-662-3318
Fax: 215-349-5849
Education:
B.S (Biology)
University of California, Los Angeles, CA, 1993.
(Clinical Research Training Award)
University of California, Los Angeles, CA, 1995.
M.D.
Temple University School of Medicine, Philadelphia, PA, 1999.
(Molecular Signaling Section, Cancer Research Training Fellowship)
NIH, NCI, 2005.
Permanent link
 
Perelman School of Medicine > Faculty > Search

Selected Publications

Hew KE, Miller PC, El-Ashry D, Sun J, Besser AH, Ince TA, Gu M, Wei Z, Zhang G, Brafford P, Gao W, Lu Y, Mills GB, Slingerland JM, Simpkins F: MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer. Clin Cancer Res 22(4):935-47, Feb 2016.

George E, Kim H, Tanyi J, Ragland R, Brown E, Zhang R, Brafford P, Sproesser K, Beqiri M, Vultur A, Krepler C, Lee R, Weis B, Nathanson K, Lu Y, Mills G, Makvandi M, Mach R, Morgan M, Herlyn M, Simpkins F: A novel orthotopic ovarian patient derived xenograft model platform to investigate novel therapies for BRCA deficient ovarian cancers. Poster, AACR, New Orleans, LA, Feb 2016.

Zhang X, Haggerty AF, Brown JC, Giuntoli R 2nd, Lin L, Simpkins F, Dean LT, Ko E, Morgan MA, Schmitz KH: The prescription or proscription of exercise in endometrial cancer care. Gynecol Oncol 139(1):155-9, Oct 2015.

Kim H, George E, Brown E, Zhang R, Krepler C, Tanyi J, Lee R, Morgan MA, Herlyn M, Simpkins, F: Targeting the ATR/CHK1 axis in BRCA1/2 mutant ovarian cancer using an orthotopic patient-derived xenograft (PDX) model. Poster, AACR, Orlando, FL, Oct 2015.

Chen J, Solomides C, Parekh H, Simpkins F, Simpkins H: Cisplatin resistance in human cervical, ovarian and lung cancer cells. Cancer Chemother Pharmacol 75(6):1217-27, Jun 2015.

Garcia-Soto A, McKenzie N, Portelance L, Castillo R, Pearson M, Hu J, Lucci JA 3rd, Lin L, Simpkins F: Phase I trial of nelfinavir added to cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer. Poster and published for ASCO. J Clin Oncol 33 (suppl; abstr TPS5619), Jun 2015.

Simpkins F, Drake R, Escobar PF, Nutter B, Rasool N2, Rose PG: A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA). Gynecol Oncol 136(2):240-5, Feb 2015.

Cui H, He Y, Krepler C, Tanyi J, Morgan MA, Burger RA, Kim S, Ko E, Ince T, Herlyn M, Simpkins F: A true orthotopic ovarian cancer patient-derived xenograft (PDX) model. Poster and published for AACR, Philadelphia, PA, Cancer Res 75; 3223, 2015.

Hew K, Miller P, Sun J, Wei Z, Zhang G, Lu Y, Mills G, Slingerland J, El-Ashry D, Simpkins F: MEK inhibition reverses antiestrogen resistance in ovarian cancer (OVCA) via alteration of cell cycle pathways and MAPK/estrogen regulated gene expression. Oral presentation and published, AACR Meeting, Marsha Rivkin Center for Ovarian Cancer Research Symposia, Seattle WA. Clin Cancer Res 21; AS31, Sep 2014.

Simpkins F, Hew K, Azzam D, Wei Z, Zhang G, Sun J, Zhang D, Jang K, Liu W, Lu Y, Mills G, Tan I, Slingerland J: Combined Src and MEK inhibition decreases ovarian cancer (OVCA) cell growth, tumorigenicity and aldehyde dehydrogenase positive tumor-initiating-cells. Poster and published for the AACR Meeting, Marsha Rivkin Center for Ovarian Cancer Research Symposia, Seattle WA, Clin Cancer Res 21; POSTER-THER-1431, Sept 2014.

back to top
Last updated: 05/13/2016
The Trustees of the University of Pennsylvania